GLP-1 Market
LLY $1149.85 ▼ -0.6% NVO $37.40 ▼ -1.3% PFE $28.12 ▼ -1.4% VKTX $30.51 ▼ -6.4% KLRA $11.03 ▼ -3.4% GPCR $28.98 ▼ -7.3% RHHBY $52.35 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

IBI3032

IBI3032

Company
Innovent Biologics Technology Limited (Shanghai R&D Center)
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 2, 2026

Find a Clinical Trial Near Me

See recruiting studies for IBI3032 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07120425

    A Study of IBI3032 in Healthy Participants

    Not yet reported Fortvita Biologics (USA)Inc. 32 participants Est. completion 2025-11-13 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT07134127

    A Study of IBI3032 in Chinese Healthy Subjects

    Not yet reported Innovent Biologics Technology Limited (Shanghai R&D Center) 40 participants Est. completion 2025-10-07 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT07160400

    A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

    Not yet reported Innovent Biologics Technology Limited (Shanghai R&D Center) 80 participants Est. completion 2026-08-10 1 site Stand-alone
    Other conditions: Part A: Healthy Part B: Overweight or Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07170319

    A Study of IBI3032 in Chinese Participants With Overweight or Obesity

    Not yet reported Innovent Biologics Technology Limited (Shanghai R&D Center) 79 participants Est. completion 2026-03-31 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: IBI3032, IBI3032 tablets

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.